Comparison of nuclear medicine therapeutics targeting PSMA among alpha-emitting nuclides

アルファ線放出核種を対象としたPSMAを標的とした核医学治療法の比較

兼田 加珠子*; 白神 宜史*; 角永 悠一郎*; 渡部 直史*; 大江 一弘*; Yin, X.*; 羽場 宏光*; 白崎 謙次*; 菊永 英寿*; 塚田 和明  ; 豊嶋 厚史*; Cardinale, J.*; Giesel, F. L.*; 深瀬 浩一*

Kaneda-Nakashima, Kazuko*; Shirakami, Yoshifumi*; Kadonaga, Yuichiro*; Watabe, Tadashi*; Oe, Kazuhiro*; Yin, X.*; Haba, Hiromitsu*; Shirasaki, Kenji*; Kikunaga, Hidetoshi*; Tsukada, Kazuaki; Toyoshima, Atsushi*; Cardinale, J.*; Giesel, F. L.*; Fukase, Koichi*

Currently, targeted alpha therapy (TAT) is a new therapy involving the administration of a therapeutic drug that combines a substance of -emitting nuclides that kill cancer cells and a drug that selectively accumulates in cancer cells. We labeled the compounds targeting prostate specific membrane antigen (PSMA) with At and Ac. PSMA is a molecule that has attracted attention as a theranostic target for prostate cancer, and several targeted radioligands have already shown therapeutic effects in patients. The results showed that At, which has a much shorter half-life, is no less cytotoxic than Ac. In At labeling, our group has also developed an original method (Shirakami Reaction). We have succeeded in obtaining a highly purified labeled product in a short timeframe using this method.